L-203-2023

Agreement ID
L-203-2023
Lead IC
NIAID
Exclusivity
Exclusive
External Party
Taurgen Malaria, Inc.
Fiscal Year
2025
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies
TAB-3424     Identification of a New Human Monoclonal Antibody that More Potently Prevents Malaria Infection